


New vaccine blocks COVID-19 and variants, plus other coronaviruses

10 May 2021, by Sarah Avery



Credit: Duke University School of Nursing

A potential new vaccine developed by members of the Duke Human Vaccine Institute has proven effective in protecting monkeys and mice from a variety of coronavirus infections-including SARS-CoV-2 as well as the original SARS-CoV-1 and related bat coronaviruses that could potentially cause the next pandemic.

The new vaccine, called a pan-coronavirus vaccine, triggers neutralizing antibodies via a nanoparticle. The nanoparticle is composed of the coronavirus part that allows it to bind to the body's cell receptors, and is formulated with a chemical booster called an adjuvant. Success in primates is highly relevant to humans.

The findings appear Monday, May 10 in the journal Nature.

"We began this work last spring with the understanding that, like all viruses, mutations would occur in the SARS-CoV-2 virus, which causes COVID-19," said senior author Barton F. Haynes, M.D., director of the Duke Human Vaccine vaccine blocked COVID-19 infection by 100%. The Institute (DHVI). "The mRNA vaccines were

already under development, so we were looking for ways to sustain their efficacy once those variants appeared.

"This approach not only provided protection against SARS-CoV-2, but the antibodies induced by the vaccine also neutralized variants of concern that originated in the United Kingdom, South Africa and Brazil," Haynes said. "And the induced antibodies reacted with quite a large panel of coronaviruses."

Haynes and colleagues, including lead author Kevin Saunders, Ph.D., director of research at DHVI, built on earlier studies involving SARS, the respiratory illness caused by a coronavirus called SARS-CoV-1. They found a person who had been infected with SARS developed antibodies capable of neutralizing multiple coronaviruses, suggesting that a pan-coronavirus might be possible.

The Achilles heel for the coronaviruses is their receptor-binding domain, located on the spike that links the viruses to receptors in human cells. While this binding site enables it to enter the body and cause infection, it can also be targeted by antibodies.

The research team identified one particular receptor-binding domain site that is present on SARS-CoV-2, its circulating variants and SARSrelated bat viruses that makes them highly vulnerable to cross-neutralizing antibodies.

The team then designed a nanoparticle displaying this vulnerable spot. The nanoparticle is combined with a small molecule adjuvant-specifically, the tolllike receptor 7 and 8 agonist called 3M-052, formulated with Alum, which was developed by 3M and the Infectious Disease Research Institute. The adjuvant boosts the body's immune response.

In tests of its effect on monkeys, the nanoparticle new vaccine also elicited significantly higher



neutralizing levels in the animals than current vaccine platforms or natural infection in humans.

"Basically what we've done is take multiple copies of a small part of the coronavirus to make the body's immune system respond to it in a heightened way," Saunders said. "We found that not only did that increase the body's ability to inhibit the virus from causing infection, but it also targets this cross-reactive site of vulnerability on the spike protein more frequently. We think that's why this vaccine is effective against SARS-CoV-1, SARS-CoV-2 and at least four of its common variants, plus additional animal coronaviruses."

"There have been three coronavirus epidemics in the past 20 years, so there is a need to develop effective vaccines that can target these pathogens prior to the next pandemic," Haynes said. "This work represents a platform that could prevent, rapidly temper, or extinguish a pandemic."

More information: Kevin O. Saunders et al. Neutralizing antibody vaccine for pandemic and preemergent coronaviruses, *Nature* (2021). <u>DOI:</u> <u>10.1038/s41586-021-03594-0</u>

Provided by Duke University School of Nursing APA citation: New vaccine blocks COVID-19 and variants, plus other coronaviruses (2021, May 10) retrieved 13 May 2021 from <u>https://medicalxpress.com/news/2021-05-vaccine-blocks-covid-variantscoronaviruses.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.